FLT3: A Prototype Receptor Tyrosine Kinase Target in AML
作者： Mark Levis
DOI: 10.1007/978-1-59745-322-6_11
关键词:
摘要: The receptor tyrosine kinase FLT3 is an important regulatory molecule in hematopoiesis and expressed on the blasts most cases of acute leukemia. Activating mutations this are present roughly 30% myeloid leukemia (AML) patients associated with a distinctly worse clinical outcome. Efforts to target mutation improve outcomes subgroup AML have led investigation several novel small-molecule inhibitors. These compounds derive from wide variety chemical classes differ significantly both their potency selectivity. review summarizes data validating as therapeutic reviews results preliminary trials using these agents for treatment harboring mutations.
springer.com
sci-hub.st 参考文章(126)
Hilary J. McKenna, Kim L. Stocking, Robert E. Miller, Kenneth Brasel, Thibaut De Smedt, Eugene Maraskovsky, Charles R. Maliszewski, David H. Lynch, Jeffrey Smith, Bali Pulendran, Eileen R. Roux, Mark Teepe, Stewart D. Lyman, Jacques J. Peschon, Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood. ,vol. 95, pp. 3489- 3497 ,(2000) , 10.1182/BLOOD.V95.11.3489
O Rosnet, C Schiff, MJ Pebusque, S Marchetto, C Tonnelle, Y Toiron, F Birg, D Birnbaum, Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood. ,vol. 82, pp. 1110- 1119 ,(1993) , 10.1182/BLOOD.V82.4.1110.1110
Quentmeier H, Meierhoff G, Drexler Hg, Dehmel U, Birnbaum D, Rosnet O, Dirks W, Gruss Hj, Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines. Leukemia. ,vol. 9, pp. 1368- 1372 ,(1995)
A. Blair, D.E. Hogge, H.J. Sutherland, Most Acute Myeloid Leukemia Progenitor Cells With Long-Term Proliferative Ability In Vitro and In Vivo Have the Phenotype CD34+/CD71−/HLA-DR− Blood. ,vol. 92, pp. 4325- 4335 ,(1998) , 10.1182/BLOOD.V92.11.4325
SD Lyman, L James, L Johnson, K Brasel, P de Vries, SS Escobar, H Downey, RR Splett, MP Beckmann, HJ McKenna, Cloning of the human homologue of the murine flt3 ligand : a growth factor for early hematopoietic progenitor cells Blood. ,vol. 83, pp. 2795- 2801 ,(1994) , 10.1182/BLOOD.V83.10.2795.2795
F Birg, M Courcoul, O Rosnet, F Bardin, MJ Pebusque, S Marchetto, A Tabilio, P Mannoni, D Birnbaum, Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages Blood. ,vol. 80, pp. 2584- 2593 ,(1992) , 10.1182/BLOOD.V80.10.2584.2584
Thelma Angeles, John Lamb, John T. Isaacs, Craig A. Dionne, Daniel J. George, Jitesh Jani, Chikara Murakata, Sustained in Vivo Regression of Dunning H Rat Prostate Cancers Treated with Combinations of Androgen Ablation and Trk Tyrosine Kinase Inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555) Cancer Research. ,vol. 59, pp. 2395- 2401 ,(1999)
CE Carow, M Levenstein, SH Kaufmann, J Chen, S Amin, P Rockwell, L Witte, MJ Borowitz, CI Civin, D Small, Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood. ,vol. 87, pp. 1089- 1096 ,(1996) , 10.1182/BLOOD.V87.3.1089.BLOODJOURNAL8731089
Masao Mizuki, Regina Fenski, Hartmut Halfter, Itaru Matsumura, Rainer Schmidt, Carsten Müller, Wolfram Grüning, Karsten Kratz-Albers, Susanne Serve, Claudia Steur, Thomas Büchner, Joachim Kienast, Yuzuru Kanakura, Wolfgang E. Berdel, Hubert Serve, Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood. ,vol. 96, pp. 3907- 3914 ,(2000) , 10.1182/BLOOD.V96.12.3907
O P Veiby, S D Lyman, F W Jacobsen, S E Jacobsen, L Cui, The flt3 ligand promotes the survival of primitive hemopoietic progenitor cells with myeloid as well as B lymphoid potential. Suppression of apoptosis and counteraction by TNF-alpha and TGF-beta. Journal of Immunology. ,vol. 157, pp. 2953- 2960 ,(1996)